A Rare Case of Canine Pericardial Malignant Mesothelioma: Clinicopathologic Findings, Diagnostic Investigations, and Clinical Course with Epirubicin Treatment
10.17555/jvc.2024.41.3.170
- Author:
Jun-Hyuk MIN
1
;
Jiwoong YOON
;
Sooyoung SON
;
Woo-Jin SONG
;
Siheon LEE
;
Youngmin YUN
;
Hyunjung PARK
;
Jongtae CHEONG
;
Alba Maria M. SHANK
;
Myung-Chul KIM
Author Information
1. College of Veterinary Medicine, Jeju National University, Jeju 63243, Korea
- Publication Type:Case Report
- From:
Journal of Veterinary Clinics
2024;41(3):170-177
- CountryRepublic of Korea
- Language:English
-
Abstract:
An adult male dog was presented for hemorrhagic pericardial effusion. Echocardiography and computed tomography revealed nodule-like lesions on the pericardium. Cytology of pericardial effusion and excisional pericardial lesions indicated neoplastic effusion. Histopathology indicated an inflamed neoplasm with a primary differential diagnosis of hemangiosarcoma and malignant mesothelioma (MM). Immunohistochemistry showed that atypical cells were positive for cytokeratin and vimentin, but negative for CD31, strongly favoring pericardial MM. Postoperative NT-proBNP level remained increased, which led to the administration of epirubicin to minimize potential cardiotoxicity. During the 4 cycles of epirubicin treatment, a total cumulative dose of 108 mg/m 2 was administrated and no effusion recurrence was observed. After a month post-completion of chemotherapy, however, pleural effusion was detected with cardiac masses. The owner requested no further diagnostic investigations and chemotherapy. Due to deteriorating conditions, the dog died 132 days after the first presentation. Our case is the first notable attempt to treat canine malignant mesothelioma with epirubicin, providing the clinicopathologic, diagnostic routine, and clinical course of the affected dog.
